GlassScriptPhysician profile
Ovidiu Alb
NPI 1356335731
$2,381.22
in general payments reported to CMS, 2019-2025
37 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $61.31 · 2021: $18.58 · 2022: $397 · 2023: $270 · 2024: $982 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.62 | 2021-2025 | Ubrelvy |
| Abbott Laboratories | $205.02 | 2022-2025 | Jot Dx, Aveir, Gallant |
| Novo Nordisk INC | $198.96 | 2019-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $197.80 | 2024 | |
| Glaxosmithkline, LLC. | $151.37 | 2020-2025 | Shingrix, Arexvy |
| Radius Health, INC. | $132.08 | 2024-2025 | |
| Astellas Pharma US INC | $113.81 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $98.89 | 2019-2022 | |
| Gilead Sciences, INC. | $59.17 | 2025 | |
| Scilex Pharmaceuticals INC. | $53.91 | 2023-2024 | Ztlido |
| Hologic Sales and Service, LLC | $53.10 | 2024-2025 | Aptima |
| Exact Sciences Corporation | $51.63 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $50.00 | 2024 | Immunocap |
| Merck Sharp & Dohme LLC | $45.61 | 2019 | |
| Horizon Therapeutics Plc | $44.84 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $41.62 | 2019 | |
| Lilly USA, LLC | $41.54 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $38.15 | 2024-2025 | Airsupra |
| Dexcom, INC. | $33.54 | 2024 | Dexcom G6 Transmitter |
| Medtronic Vascular, INC. | $32.40 | 2019 | |
| Sanofi Pasteur INC. | $30.33 | 2019-2023 | |
| Biowound Solutions, INC. | $26.39 | 2025 | Bio-Connekt |
| Sanofi-Aventis U.S. LLC | $26.31 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.08 | 2023 | Evkeeza |
| Amgen INC. | $25.00 | 2024 | Otezla, Repatha |
| Allergan, INC. | $24.09 | 2019 | |
| Bausch Health US, LLC | $22.47 | 2019 | |
| Medtronic, INC. | $21.36 | 2022 | |
| Pfizer INC. | $21.14 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $20.20 | 2025 | Rexulti |
| Boston Scientific Corporation | $18.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.00 | 2022 | |
| Zimmer Biomet Holdings, INC. | $17.86 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.03 | 2024 | Jardiance |
| Baxter Healthcare | $16.07 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $15.04 | 2023 | Amvuttra |
| Ibsa Pharma INC. | $13.05 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ovidiu Alb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.